RU2012146986A - Цефемовые соединения, содержащие катехольную группу - Google Patents
Цефемовые соединения, содержащие катехольную группу Download PDFInfo
- Publication number
- RU2012146986A RU2012146986A RU2012146986/04A RU2012146986A RU2012146986A RU 2012146986 A RU2012146986 A RU 2012146986A RU 2012146986/04 A RU2012146986/04 A RU 2012146986/04A RU 2012146986 A RU2012146986 A RU 2012146986A RU 2012146986 A RU2012146986 A RU 2012146986A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- ester
- amino
- pharmaceutically acceptable
- ring
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 46
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 229910052736 halogen Inorganic materials 0.000 claims abstract 11
- 150000002367 halogens Chemical class 0.000 claims abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 239000001257 hydrogen Substances 0.000 claims abstract 10
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract 3
- 125000004429 atom Chemical group 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000005750 substituted cyclic group Chemical group 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 239000012453 solvate Substances 0.000 claims 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- -1 amino compound Chemical class 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
- C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
- C07D505/16—Nitrogen atoms
- C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
- C07D501/56—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010087131 | 2010-04-05 | ||
| JP2010-087131 | 2010-04-05 | ||
| JP2010-274180 | 2010-12-09 | ||
| JP2010274180 | 2010-12-09 | ||
| PCT/JP2011/058498 WO2011125967A1 (ja) | 2010-04-05 | 2011-04-04 | カテコール基を有するセフェム化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012146986A true RU2012146986A (ru) | 2014-05-20 |
Family
ID=44762902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012146986/04A RU2012146986A (ru) | 2010-04-05 | 2011-04-04 | Цефемовые соединения, содержащие катехольную группу |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9145425B2 (enExample) |
| EP (1) | EP2557082A4 (enExample) |
| JP (1) | JP5909441B2 (enExample) |
| KR (1) | KR20130018845A (enExample) |
| CN (1) | CN102918048A (enExample) |
| AR (1) | AR081758A1 (enExample) |
| AU (1) | AU2011236933A1 (enExample) |
| CA (1) | CA2795322A1 (enExample) |
| IN (1) | IN2012CN09242A (enExample) |
| MX (1) | MX2012011521A (enExample) |
| RU (1) | RU2012146986A (enExample) |
| TW (1) | TW201139451A (enExample) |
| UY (1) | UY33315A (enExample) |
| WO (1) | WO2011125967A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009049086A1 (en) | 2007-10-09 | 2009-04-16 | Larry Sutton | Broad spectrum beta-lactamase inhibitors |
| LT2960244T (lt) * | 2008-10-31 | 2016-11-25 | Shionogi & Co., Ltd. | Cefalosporinas, turintis katecholio grupę |
| JP5852559B2 (ja) * | 2010-04-05 | 2016-02-03 | 塩野義製薬株式会社 | 擬似カテコール基を有するセフェム化合物 |
| JP5852562B2 (ja) * | 2010-04-28 | 2016-02-03 | 塩野義製薬株式会社 | 新規なセフェム誘導体 |
| EP2703406A4 (en) | 2011-04-28 | 2015-08-05 | Shionogi & Co | NOVEL CEPHEM COMPOUND HAVING THE CATÉCHOL STRUCTURE OR A STRUCTURE CLOSE TO CATÉCHOL |
| US9242999B2 (en) | 2011-06-27 | 2016-01-26 | Shionogi & Co., Ltd. | Cephem compound having pyridinium group |
| TWI547496B (zh) * | 2011-10-04 | 2016-09-01 | 葛蘭素集團公司 | 抗菌化合物 |
| CN103958527A (zh) | 2011-10-04 | 2014-07-30 | 盐野义制药株式会社 | 具有儿茶酚基团的头孢烯衍生物 |
| UY35103A (es) * | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| WO2014069649A1 (en) | 2012-10-29 | 2014-05-08 | Shionogi & Co., Ltd. | Processes for production of intermediates for 2-alkyl cephem compounds |
| US9139743B2 (en) * | 2013-01-31 | 2015-09-22 | Xerox Corporation | Malic acid derivatives as amorphous materials for phase change ink |
| JP6783497B2 (ja) * | 2014-09-04 | 2020-11-11 | 塩野義製薬株式会社 | セファロスポリン誘導体の中間体およびその製造方法 |
| ES2893424T3 (es) * | 2014-09-04 | 2022-02-09 | Shionogi & Co | Sal de derivado de cefalosporina, su forma sólida cristalina y método para producirla |
| CN104817604B (zh) * | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
| KR20180011843A (ko) | 2015-06-11 | 2018-02-02 | 바실리어 파마슈티카 인터내셔널 리미티드 | 유출-펌프 억제제 및 이의 치료적 용도 |
| KR102135230B1 (ko) | 2015-12-10 | 2020-07-17 | 나에자-알지엠 파마슈티칼스 유엘씨 | 세펨 화합물, 그의 제조 및 용도 |
| WO2017199227A1 (en) | 2016-05-20 | 2017-11-23 | S & I Ophthalmic, Llc. | Process for preparation of 3,4-dihydroxy-2-methyl benzoic acid alkylester |
| WO2020048829A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 3,9-diazaspiro[5.5]undecane compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| JP2022507470A (ja) * | 2018-11-13 | 2022-01-18 | 南京聖和薬業股▲ふん▼有限公司 | モノバクタム化合物及びその使用 |
| WO2020184399A1 (ja) * | 2019-03-08 | 2020-09-17 | 塩野義製薬株式会社 | 抗菌用医薬組成物 |
| WO2020206381A1 (en) * | 2019-04-03 | 2020-10-08 | Sutton Larry D | Cephem compounds with latent reactive groups and methods of using and making same |
| CN114846016B (zh) * | 2020-01-22 | 2024-12-13 | 上海森辉医药有限公司 | 头孢类抗菌化合物及其在医药上的应用 |
| CN115087633A (zh) | 2020-02-11 | 2022-09-20 | 凯米诺瓦有限公司 | 由(r)-2-氨基丁酸合成s-氟丁酰草胺的方法 |
| GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
| CN111714490B (zh) * | 2020-07-20 | 2021-07-06 | 广东工业大学 | 一种化合物在制备抑制细菌群体感应系统药物中的应用 |
| WO2022152146A1 (zh) * | 2021-01-12 | 2022-07-21 | 上海森辉医药有限公司 | 一种头孢类抗菌化合物及其制备方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
| JPS57118588A (en) | 1981-11-26 | 1982-07-23 | Toyama Chem Co Ltd | Novel cephalosporin |
| DE3207840A1 (de) | 1982-03-04 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | "cephalosporinderivate und verfahren zu ihrer herstellung" |
| DE3470314D1 (en) | 1983-01-21 | 1988-05-11 | Beecham Group Plc | Beta-lactam antibacterial agents |
| NO165842C (no) | 1984-04-23 | 1991-04-17 | Takeda Chemical Industries Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser. |
| EP0168177A3 (en) | 1984-06-28 | 1987-04-01 | Pfizer Limited | Cephalosporin antibiotics |
| EP0203271B1 (en) | 1985-03-01 | 1993-05-26 | Takeda Chemical Industries, Ltd. | Antibacterial compounds, their production and use |
| JPH068300B2 (ja) | 1985-08-02 | 1994-02-02 | 萬有製薬株式会社 | 新規セフアロスポリン誘導体 |
| EP0211656A3 (en) | 1985-08-10 | 1988-03-09 | Beecham Group Plc | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them |
| ATE82976T1 (de) | 1985-09-03 | 1992-12-15 | Otsuka Kagaku Kk | Cephalosporinderivate. |
| JPS62158291A (ja) | 1986-01-07 | 1987-07-14 | Sagami Chem Res Center | セフアロスポリン誘導体 |
| EP0346465B1 (en) | 1986-04-14 | 1993-08-11 | Banyu Pharmaceutical Co., Ltd. | 1-carboxy-1-vyniloxyiminoaminothiazole cephalosporing derivatives and process for their preparation |
| EP0241901B1 (en) | 1986-04-14 | 1994-08-24 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| IE61679B1 (en) | 1987-08-10 | 1994-11-16 | Fujisawa Pharmaceutical Co | Water-soluble antibiotic composition and water-soluble salts of new cephem compounds |
| GB8719875D0 (en) | 1987-08-22 | 1987-09-30 | Beecham Group Plc | Compounds |
| JPH0228185A (ja) | 1988-04-14 | 1990-01-30 | Tanabe Seiyaku Co Ltd | セファロスポリン化合物及びその合成中間体 |
| US5149803A (en) | 1988-05-10 | 1992-09-22 | Imperial Chemical Industries Plc | Intermediates for cephalosporin compounds |
| GB8811055D0 (en) | 1988-05-10 | 1988-06-15 | Ici Plc | Antibiotic compounds |
| US5244890A (en) * | 1988-06-06 | 1993-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
| PH25965A (en) | 1988-06-06 | 1992-01-13 | Fujisawa Pharmaceutical Co | New cephem compounds which have antimicrobial activities |
| GB8813945D0 (en) | 1988-06-13 | 1988-07-20 | Fujisawa Pharmaceutical Co | New cephem compounds & process for preparation thereof |
| GB8817653D0 (en) | 1988-07-25 | 1988-09-01 | Fujisawa Pharmaceutical Co | New cephem compounds & processes for preparation thereof |
| CA2005787A1 (en) | 1988-12-29 | 1990-06-29 | Masao Wada | Cephalosporin compounds |
| JPH02275886A (ja) | 1988-12-29 | 1990-11-09 | Tanabe Seiyaku Co Ltd | セファロスポリン化合物及びその製法 |
| US5143910A (en) | 1989-09-07 | 1992-09-01 | Shionogi & Co., Ltd. | Piperaziniocephalosporins |
| GB9005246D0 (en) | 1990-03-08 | 1990-05-02 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| US5095012A (en) | 1990-08-23 | 1992-03-10 | Bristol-Myers Squibb Company | Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof |
| US5126336A (en) | 1990-08-23 | 1992-06-30 | Bristol-Myers Squibb Company | Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof |
| US5234920A (en) | 1990-08-23 | 1993-08-10 | Bristol-Myers Squibb Company | Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof |
| US5194433A (en) | 1990-11-13 | 1993-03-16 | Bristol-Myers Squibb Company | Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof |
| GB9111406D0 (en) | 1991-05-28 | 1991-07-17 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| GB9118672D0 (en) | 1991-08-30 | 1991-10-16 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| EP0628562A1 (fr) | 1993-06-10 | 1994-12-14 | Roussel Uclaf | Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments |
| US5532235A (en) | 1995-01-17 | 1996-07-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AU1694099A (en) | 1997-12-26 | 1999-07-19 | Cheil Jedang Corporation | Cephem derivatives and a method for producing the compounds and an antibacterialcomposition containing the compounds |
| TW200305422A (en) * | 2002-03-18 | 2003-11-01 | Shionogi & Co | Broad spectrum cefem compounds |
| US6713625B2 (en) | 2002-05-23 | 2004-03-30 | Orchid Chemicals & Pharmaceuticals Ltd. | Process for the preparation of cefditoren using the thioester of thiazolylacetic acid |
| AU2003251627A1 (en) | 2002-06-27 | 2004-01-19 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydrobromide |
| JP3928086B2 (ja) | 2005-03-29 | 2007-06-13 | 塩野義製薬株式会社 | ３−プロペニルセフェム誘導体 |
| WO2007096740A2 (en) | 2006-02-20 | 2007-08-30 | Orchid Research Laboratories Limited | Novel cephalosporins |
| EP1994035A1 (en) | 2006-03-16 | 2008-11-26 | Astellas Pharma Inc. | Cephem compounds and use as antimicrobial agents |
| ES2436020T3 (es) | 2006-09-29 | 2013-12-26 | Grünenthal GmbH | Derivados de sulfonamida sustituidos |
| SI2074120T1 (sl) | 2007-10-25 | 2010-06-30 | Exelixis Inc | Tropan spojine |
| JP5713525B2 (ja) | 2008-09-30 | 2015-05-07 | 三菱マテリアル株式会社 | 導電性インク組成物及び該組成物を用いた太陽電池セル及び太陽電池モジュールの製造方法 |
| JP2010087130A (ja) | 2008-09-30 | 2010-04-15 | Toyota Motor Corp | 半導体装置の製造方法 |
| LT2960244T (lt) | 2008-10-31 | 2016-11-25 | Shionogi & Co., Ltd. | Cefalosporinas, turintis katecholio grupę |
| JP2010104035A (ja) | 2010-01-25 | 2010-05-06 | Toshiba Corp | 受信装置及び受信方法 |
| JP5852559B2 (ja) * | 2010-04-05 | 2016-02-03 | 塩野義製薬株式会社 | 擬似カテコール基を有するセフェム化合物 |
| JP5852562B2 (ja) | 2010-04-28 | 2016-02-03 | 塩野義製薬株式会社 | 新規なセフェム誘導体 |
-
2011
- 2011-04-04 KR KR1020127028893A patent/KR20130018845A/ko not_active Withdrawn
- 2011-04-04 WO PCT/JP2011/058498 patent/WO2011125967A1/ja not_active Ceased
- 2011-04-04 CA CA2795322A patent/CA2795322A1/en not_active Abandoned
- 2011-04-04 JP JP2012509646A patent/JP5909441B2/ja not_active Expired - Fee Related
- 2011-04-04 RU RU2012146986/04A patent/RU2012146986A/ru not_active Application Discontinuation
- 2011-04-04 MX MX2012011521A patent/MX2012011521A/es not_active Application Discontinuation
- 2011-04-04 AU AU2011236933A patent/AU2011236933A1/en not_active Abandoned
- 2011-04-04 CN CN2011800277729A patent/CN102918048A/zh active Pending
- 2011-04-04 US US13/639,412 patent/US9145425B2/en not_active Expired - Fee Related
- 2011-04-04 EP EP11765867.4A patent/EP2557082A4/en not_active Withdrawn
- 2011-04-04 IN IN9242CHN2012 patent/IN2012CN09242A/en unknown
- 2011-04-05 AR ARP110101141A patent/AR081758A1/es unknown
- 2011-04-05 UY UY0001033315A patent/UY33315A/es not_active Application Discontinuation
- 2011-04-06 TW TW100111734A patent/TW201139451A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201139451A (en) | 2011-11-16 |
| CN102918048A (zh) | 2013-02-06 |
| KR20130018845A (ko) | 2013-02-25 |
| MX2012011521A (es) | 2013-03-08 |
| CA2795322A1 (en) | 2011-10-13 |
| EP2557082A4 (en) | 2013-08-28 |
| AU2011236933A1 (en) | 2013-05-02 |
| JP5909441B2 (ja) | 2016-04-26 |
| WO2011125967A1 (ja) | 2011-10-13 |
| AR081758A1 (es) | 2012-10-17 |
| US20130102583A1 (en) | 2013-04-25 |
| UY33315A (es) | 2011-10-31 |
| US9145425B2 (en) | 2015-09-29 |
| JPWO2011125967A1 (ja) | 2013-07-11 |
| IN2012CN09242A (enExample) | 2015-08-21 |
| EP2557082A1 (en) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012146986A (ru) | Цефемовые соединения, содержащие катехольную группу | |
| EA201071034A1 (ru) | Новые макроциклические ингибиторы репликаций вируса гепатита с | |
| EA200600892A1 (ru) | Новые хинолиновые производные | |
| EA200800413A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| CY1107084T1 (el) | Παραγωγα πυρρολοπυριδαζινης | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| CY1113809T1 (el) | Μακροκυκλικα καρβοξυλικα οξεα και ακυλοσουλφοναμιδικες ενωσεις ως αναστολεις της αντιγραφης του hcv | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| EA200501820A1 (ru) | Терапевтические средства для лечения боли | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| UA116616C2 (uk) | Інгібітори hcv серинової протеази, отримані з макроциклічного проліну | |
| EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| EA200500312A1 (ru) | Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз | |
| EA200700099A1 (ru) | Производные пиридина | |
| RU2012157293A (ru) | Макроциклические соединения, применимые в качестве ингибиторов гистондеацетилаз | |
| RU2014113539A (ru) | Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| EA201690135A1 (ru) | Трициклические соединения бензоксаборола и их применение | |
| DK1664016T3 (da) | Terapeutiske midler, der er anvendelige til behandling af smerter | |
| RU2011105810A (ru) | Азотсодержащие бициклические гетероциклические соединения | |
| RU2006109004A (ru) | 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны | |
| RU2007118727A (ru) | Ингибиторы mif | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150717 |